Envoy Medical, INC

Envoy Medical, Inc. has terminated its At-The-Market (ATM) equity offering agreement, previously allowing for up to $15 million in stock sales, citing confidence in its current capital position.

Envoy Medical, Inc. announced updated compensation terms and significant equity grants for CEO Brent Lucas tied to strategic performance and FDA approval milestones.

Envoy Medical has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, potentially involving a reverse stock split.

Envoy Medical's stockholders approved amendments to the Equity Incentive Plan and Employee Stock Purchase Plan, increasing share availability.

Envoy Medical announced the completion of its pivotal clinical trial enrollment for the Acclaim cochlear implant and a significant capital raise, advancing its path toward FDA approval.

Envoy Medical, Inc. has expanded its Board of Directors to seven members with the appointment of industry veteran Charles S. McKhann.

Envoy Medical, Inc. filed its Q1 2026 Form 10-Q, detailing financial performance, progress on its Acclaim CI product, and ongoing operational challenges.

Envoy Medical reported increased net losses in Q3 2025, but advanced its pivotal Acclaim CI clinical trial and raised significant capital through offerings and warrant exercises, while addressing Nasdaq compliance and internal control weaknesses.

Envoy Medical, a hearing health company, reported increased net losses and a growing accumulated deficit for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite advancing its Acclaim CI clinical trials.

Envoy Medical reports a net loss for Q1 2025, but highlights progress with its Acclaim Cochlear Implant clinical trial and ongoing development efforts.

Envoy Medical obtained a $10 million loan from GAT Funding, while reporting a net loss for Q3 2024 and providing updates on its Acclaim CI clinical trial progress.

Envoy Medical reports a net loss of $10.2 million for the first half of 2024, while advancing the development of its Acclaim Cochlear Implant.

Envoy Medical, Inc. has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct a typographical error in an auditor's consent and to include updated certifications.

Envoy Medical, Inc. reported a significant net loss and accumulated deficit for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite fully enrolling its pivotal clinical trial for the Acclaim CI.

Envoy Medical's 2024 10-K filing reveals ongoing losses, efforts to advance its Acclaim CI, and material weaknesses in internal controls, raising substantial doubt about its ability to continue as a going concern.

Envoy Medical's 10-K filing details the rights and privileges of its Class A common stock and public warrants, including voting, dividend, and liquidation rights, as well as warrant exercise and redemption terms.

CEO Brent Lucas acquired 32,856 shares of Envoy Medical, Inc. Class A Common Stock through the company's Employee Stock Purchase Plan.

Director Chas McKhann was granted 100,000 stock options in Envoy Medical, Inc. as part of a long-term incentive plan.

Glen A. Taylor, a Director and 10% owner of Envoy Medical, Inc., acquired 18.75 million shares of Class A Common Stock and 30 million warrants at $0.40 per share.

Envoy Medical's Interim CFO, Robert Potashnick, has acquired 15,000 stock options with a $0.53 exercise price, vesting over several years.

Envoy Medical CEO Brent T. Lucas reported significant beneficial ownership of Class A Common Stock and various derivative securities, including new stock options.

Envoy Medical's CEO, Brent T. Lucas, acquired 18,105 shares of Class A Common Stock through an employee stock purchase plan.

Envoy Medical's 2026 proxy statement outlines key proposals including director elections, auditor ratification, and significant equity plan amendments.

Envoy Medical, Inc. calls a Special Meeting to approve the issuance of warrants and underlying Class A Common Stock to comply with Nasdaq listing rules following a recent securities offering.

Envoy Medical will hold its annual stockholder meeting on May 28, 2025, seeking votes on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Envoy Medical is holding its 2025 Annual Meeting of Stockholders to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the equity incentive plan.

Envoy Medical, Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Envoy Medical will hold its 2024 Annual Meeting of Stockholders on November 14, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

Envoy Medical, Inc. has filed an S-1MEF registration statement to offer an additional $13,437,500 in common stock and various warrants.

Envoy Medical, Inc. has amended its engagement letter with H.C. Wainwright & Co., LLC, adjusting fees and extending the term for a registered equity offering aiming to raise at least $30 million.

Envoy Medical, Inc. announces a new public offering of up to $25 million in Class A Common Stock and Warrants to fund its pivotal clinical study, while facing Nasdaq compliance challenges.

Envoy Medical, a hearing health company, is conducting a new offering of common stock and warrants to fund operations, while simultaneously addressing Nasdaq compliance issues and ongoing clinical trials for its Acclaim CI.

Envoy Medical, a hearing health company, filed an S-1/A registration statement to allow selling stockholders to resell up to 15.1 million shares, while detailing ongoing clinical trials for its Acclaim CI, significant financial losses, and Nasdaq compliance challenges.

Envoy Medical, a hearing health company, filed an S-1 registration statement for the resale of over 15 million shares by selling stockholders, while advancing its Acclaim cochlear implant clinical trials and addressing Nasdaq listing compliance.

Glen A. Taylor increased his beneficial ownership in Envoy Medical, Inc. to 84.8% through a $7.5 million stock and warrant purchase.

Glen A. Taylor, Chairman of Taylor Corporation, has increased his beneficial ownership in Envoy Medical, Inc. to 44.2% of Class A Common Stock through various acquisitions and warrant exercises.

Investment firm Bleichroeder LP reports a 9.99% beneficial ownership stake in Envoy Medical, Inc. through common stock and warrants.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed a Schedule 13G reporting a 3.1% beneficial ownership stake in Envoy Medical, Inc. through warrant holdings.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri have jointly disclosed a 7.87% beneficial ownership stake in Envoy Medical, Inc. through warrants.

Alta Partners LLC has disclosed a passive 8.25% beneficial ownership stake in Envoy Medical, Inc.'s Class A Common Stock.

Aristeia Capital, L.L.C. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.74% in Envoy Medical, Inc.'s redeemable warrants, indicating a reduction from a previously reportable stake.

Walleye Capital LLC has filed an amended Schedule 13G, reporting a 2.72% beneficial ownership stake in Envoy Medical, Inc.'s redeemable warrants as of December 31, 2024.